<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02707861</url>
  </required_header>
  <id_info>
    <org_study_id>TMB-311</org_study_id>
    <nct_id>NCT02707861</nct_id>
  </id_info>
  <brief_title>Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1</brief_title>
  <official_title>A Phase 3, Multicenter, Expanded Access Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant (MDR) HIV-1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TaiMed Biologics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Westat</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>TaiMed Biologics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ibalizumab is a monoclonal antibody that works by blocking HIV entry into the immune system
      cells (CD4+ or T-cells) the virus typically infects. Ibalizumab is intended for use in
      combination with other anti-HIV drugs in people with multi-drug resistant HIV and limited
      treatment options. This study will collect further information on the safety and tolerability
      of intravenously administered (IV) ibalizumab combined with an optimized background regimen
      for treating multi-drug resistant HIV-1 infection, and will provide continuing access to
      ibalizumab for patients completing a prior ibalizumab clinical trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will enroll into one of two study cohorts. Cohort 1 will provide continued
      administration of IV ibalizumab for patients completing a prior ibalizumab clinical trial
      (TaiMed-sponsored or Investigator-Sponsored). Patients will continue to receive IV infusions
      of ibalizumab at the dosage assigned in the previous study - either 800 mg once every two
      weeks, or 2000 mg once every four weeks.

      Cohort 2 will provide IV ibalizumab, 800 mg once every two weeks, for qualifying patients
      with multi-drug resistant HIV-1 and limited treatment options who have never previously
      received ibalizumab.

      Participants may continue in this study for 48 weeks, or until ibalizumab becomes
      commercially available, whichever occurs first.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of ibalizumab + OBR assessed by the occurrence of Adverse Events and Discontinuations</measure>
    <time_frame>Through 48 weeks</time_frame>
    <description>Safety and tolerability of ibalizumab combined with optimized background regimen, as assessed by the occurrence of Adverse Events and Discontinuations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effectiveness of ibalizumab + OBR by Viral Load Log10 Change from Baseline (Cohort 2 only)</measure>
    <time_frame>At 7 days</time_frame>
    <description>Proportion of patients in Cohort 2 achieving at least a 0.5 log10 decrease from Baseline in viral load at Day 7 of the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIV Resistance</measure>
    <time_frame>Through 48 weeks</time_frame>
    <description>HIV-1 sensitivity/susceptibility changes associated with virologic failure after administration of ibalizumab, as assessed by genotypic and phenotypic analysis of samples collected upon the occurrence of virologic failure as compared with Baseline samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of ibalizumab + OBR by Viral Suppression to &lt;50 Copies (Cohort 2 only)</measure>
    <time_frame>Through 48 weeks</time_frame>
    <description>Proportion of patients in Cohort 2 with HIV-1 RNA levels &lt;50 copies/mL at protocol-specified time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of ibalizumab + OBR by Viral Suppression to &lt;400 Copies (Cohort 2 only)</measure>
    <time_frame>Through 48 weeks</time_frame>
    <description>Proportion of patients in Cohort 2 with HIV-1 RNA levels &lt;400 copies/mL at protocol-specified time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of ibalizumab + OBR by Mean Change in Viral Load from Baseline (Cohort 2 only)</measure>
    <time_frame>Through 48 weeks</time_frame>
    <description>The mean change in viral load from Baseline measurement at study Day 7, and all other assessment time points for patients in Cohort 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of ibalizumab + OBR by 0.5 Log10 Decrease in Viral Load from Baseline (Cohort 2 only)</measure>
    <time_frame>Through 48 weeks</time_frame>
    <description>The proportion of patients in Cohort 2 achieving at least a 0.5 log10 decrease in viral load from Baseline measurement at all assessment time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of ibalizumab + OBR by 1.0 Log10 Decrease in Viral Load from Baseline (Cohort 2 only)</measure>
    <time_frame>Through 48 weeks</time_frame>
    <description>The proportion of patients in Cohort 2 achieving at least a 1.0 log10 decrease in viral load from Baseline measurement at all assessment time points</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV ibalizumab (combined with optimized background regimen):
800 mg once every two weeks for patients receiving that dosage on prior, successfully completed ibalizumab clinical trial
OR
2000 mg once every four weeks for patients receiving that dosage on prior, successfully completed ibalizumab clinical trial
Administered for 48 weeks, or until ibalizumab becomes commercially available</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV ibalizumab (combined with optimized background regimen):
800 mg once every two weeks for qualifying patients who have never received ibalizumab
Administered for 48 weeks, or until ibalizumab becomes commercially available</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ibalizumab</intervention_name>
    <description>Intravenous infusion of humanized monoclonal antibody binding with a region of Domain 2 of CD4 receptor, blocking post-attachment conformational changes necessary for HIV cell entry</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>TNX-355, Hu5A8</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Optimized Background Regimen</intervention_name>
    <description>An investigator-selected, standard-of-care combination regimen of antiretroviral agents for treating HIV-1 infection, selected based upon patient treatment history and the results of previous viral resistance testing. The combination must contain at least one agent other than ibalizumab to which the patient's virus is sensitive (susceptible).</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        (Cohort 1)

          -  Currently receiving ibalizumab via other TaiMed-sponsored or investigator-Sponsored
             protocol

          -  Are capable of understanding and have voluntarily signed the informed consent document

        (Cohort 2)

          -  18 years of age or older

          -  Are capable of understanding and have voluntarily signed the informed consent document

          -  Have documented HIV-1 infection by official, signed, written history (e.g., laboratory
             report), otherwise an HIV-antibody test will be performed

          -  Are able and willing to comply with all protocol requirements and procedures

          -  Have a viral load &gt;1,000 copies/mL and documented resistance to at least one
             antiretroviral medication from each of three classes of antiretroviral medications as
             measured by previous viral resistance testing (resistance testing is not provided by
             the study for qualification purposes)

          -  Have a history of at least 6 months on antiretroviral treatment

          -  Are receiving a failing antiretroviral regimen OR have failed and are off therapy

          -  Have viral sensitivity/susceptibility to at least one antiretroviral agent, other than
             ibalizumab, as determined by previous resistance test performed within 6 months of
             screening and be willing and able to be treated with at least one agent to which the
             patient's viral isolate is fully sensitive/susceptible according to the resistance
             tests used for screening as a component of OBR

          -  If sexually active, are willing to use an effective method of contraception during the
             study and for 30 days after the last administration of the study drug

        Exclusion Criteria:

        (Cohort 1)

          -  There are no Exclusion Criteria for patients meeting the Inclusion Criteria for Cohort
             1

        (Cohort 2)

          -  Eligible for participation in other TaiMed-sponsored clinical trials of ibalizumab

          -  Any significant diseases (other than HIV-1 infection) or clinically significant
             findings, including psychiatric and behavioral problems, determined from screening,
             medical history and/or physical examination that, in the investigator's opinion, would
             preclude the patient from participating in this study

          -  Any significant acute illness within 1 week before the first administration of
             investigational medication on this study

          -  Any active infection secondary to HIV requiring acute therapy; however, patients that
             require maintenance therapy (i.e., secondary prophylaxis for opportunistic infections)
             will be eligible for the study.

          -  Any immunomodulating therapy (including interferon), systemic steroids, or systemic
             chemotherapy within 4 weeks before Day 0

          -  Any prior exposure to ibalizumab (formerly TNX-355 and Hu5A8)

          -  Any vaccination within 7 days before Day 0

          -  Any female patient who either is pregnant, intends to become pregnant, or is currently
             breastfeeding

          -  Any current alcohol or illicit drug use that, in the investigator's opinion, will
             interfere with the patient's ability to comply with the study schedule and protocol
             evaluations

          -  Any previous clinically significant allergy or hypersensitivity to any excipient in
             the ibalizumab formulation

          -  Any radiation therapy during the 28 days before first administration of
             investigational medication on this study

          -  Any clinically significant Grade 3 or 4 laboratory abnormality according to the
             Division of AIDS (DAIDS) grading scale, except for the following asymptomatic Grade 3
             events:

               -  triglyceride elevation

               -  total cholesterol elevation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanley T. Lewis, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>TaiMed Biologics Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine Anderson, PhD</last_name>
    <phone>713-353-7911</phone>
    <email>christineanderson@westat.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tracy Wolbach</last_name>
    <phone>240-453-2658</phone>
    <email>tracywolbach@westat.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Long Beach Education and Research Consultants</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leevi Camus</last_name>
      <phone>562-624-4943</phone>
      <email>lcamus@drschneiderid.com</email>
    </contact>
    <investigator>
      <last_name>Jerome DeVente, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern California Permanente Medical Group</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cecia Villarin</last_name>
      <phone>323-783-8172</phone>
      <phone_ext>363</phone_ext>
      <email>Cecia.K.Villarin@kp.org</email>
    </contact>
    <investigator>
      <last_name>William Towner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ruane Medical and Clinical Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dani Ain</last_name>
      <phone>323-954-0400</phone>
      <phone_ext>236</phone_ext>
      <email>dain@ruanemedical.com</email>
    </contact>
    <investigator>
      <last_name>Michael Gottlieb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charles R. Drew University of Medicine and Science, Clinical and Translational Research Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90059</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurice Pitts</last_name>
      <phone>323-568-3359</phone>
      <email>orwildapitts@cdrewu.edu</email>
    </contact>
    <investigator>
      <last_name>Wilbert Jordan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anthony Mills MD Inc.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joey Fragoso</last_name>
      <phone>310-550-2271</phone>
      <email>joey.fragoso@millsclinicalresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Ron Knight</last_name>
      <phone>310.550.2271</phone>
      <email>ron@tonymillsmd.com</email>
    </contact_backup>
    <investigator>
      <last_name>Tony Mills, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Palmtree Clinical Research, Inc.</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik Hernandez</last_name>
      <phone>760-778-7799</phone>
      <email>Ehernandez@palmtreeclinical.com</email>
    </contact>
    <contact_backup>
      <last_name>Shayna Phillips</last_name>
      <phone>760-778-7799</phone>
      <email>sphillips@palmtreeclinical.com</email>
    </contact_backup>
    <investigator>
      <last_name>Richard Loftus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>eStudy Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shanette Merrick</last_name>
      <phone>415-353-0800</phone>
      <email>shanette@questclinical.com</email>
    </contact>
    <investigator>
      <last_name>Sandra Win, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Foundation Research Institute</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Kirk</last_name>
      <phone>415-833-3480</phone>
      <email>susan.f.kirk@kp.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Fessel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie Andrews</last_name>
      <phone>203-785-3557</phone>
      <email>laurie.andrews@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Brinda Emu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University School of Medicine</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maximiliano Menna</last_name>
      <phone>202-444-0371</phone>
      <email>mpm229@georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Princy Kumar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gary Richmond, MD, PA</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vernon F Appleby, RN</last_name>
      <phone>954-524-2250</phone>
      <phone_ext>211</phone_ext>
      <email>vfappleby@earthlink.net</email>
    </contact>
    <investigator>
      <last_name>Gary Richmond, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Dinsmore, RN, ACRN</last_name>
      <phone>407-409-7125</phone>
      <email>jdinsmore@oicorlando.com</email>
    </contact>
    <investigator>
      <last_name>Edwin DeJesus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Triple O Research Institute</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Whitney Rahfeldt, RN</last_name>
      <phone>561-855-7871</phone>
      <email>wrahfeldt@tripleoresearch.com</email>
    </contact>
    <investigator>
      <last_name>Olayemi Osiyemi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AIDS Research Consortium of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30312</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bentley Sweeton</last_name>
      <phone>404-876-2317</phone>
      <phone_ext>124</phone_ext>
      <email>BentleyS@arcatlanta.org</email>
    </contact>
    <investigator>
      <last_name>Melanie Thompson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Institute of Allergy &amp; Infectious Diseases</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Central West Clinical Research</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LaWanda Bishop</last_name>
      <phone>314-652-0100</phone>
      <phone_ext>*823</phone_ext>
      <email>LBishop.CWHresearch@gmail.com</email>
    </contact>
    <investigator>
      <last_name>David Parks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chelsea Village Medical</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lynne Bartell</last_name>
      <phone>212-929-2629</phone>
      <email>Lynne@CVMNYC.COM</email>
    </contact>
    <investigator>
      <last_name>Alexander McMeeking, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jacobi Medical Center</name>
      <address>
        <city>The Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelo Seda, RN</last_name>
      <phone>718-918-3662</phone>
      <email>Angelo.Seda@nbhn.net</email>
    </contact>
    <investigator>
      <last_name>Jason Leider, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rochelle Olivera</last_name>
      <phone>252-744-5700</phone>
      <email>oliverar@ecu.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Cook, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Jude's Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kim Allison</last_name>
      <phone>901-595-3252</phone>
      <email>Kim.allison@stjude.org</email>
    </contact>
    <investigator>
      <last_name>Katherine Knapp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Texas Infectious Disease Consultants</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelby Richardson, LVN</last_name>
      <phone>214-276-5646</phone>
      <email>shelby.richardson@ntidc.org</email>
    </contact>
    <contact_backup>
      <last_name>Bryan King, LVN</last_name>
      <phone>214-276-5646</phone>
      <email>bryan.king@ntidc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Louis Sloan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Crofoot Research Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charles Sydnor</last_name>
      <phone>713-526-0005</phone>
      <email>Charless@crofootmd.com</email>
    </contact>
    <investigator>
      <last_name>Gordon E Crofoot, Jr., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Access Network</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A.J. Sarabia</last_name>
      <phone>713-526-7732</phone>
      <email>aj.sarabia@theschraderclinic.com</email>
    </contact>
    <investigator>
      <last_name>Shannon Schrader, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research PR, Inc.</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yolanda Robles-Cabrera, RN, BSN</last_name>
      <phone>787.723.5945</phone>
      <email>yrobles@clinicalresearchpr.com</email>
    </contact>
    <investigator>
      <last_name>Javier Morales, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2016</study_first_submitted>
  <study_first_submitted_qc>March 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2016</study_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Resistant</keyword>
  <keyword>Salvage</keyword>
  <keyword>ibalizumab</keyword>
  <keyword>antibody</keyword>
  <keyword>AIDS</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

